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Edited by Jesus AvilaAbstract Mutations in the tau gene, which is located on chro-
mosome 17, were found causative for autosomal dominantly
inherited frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17). To determine if cognitive deﬁcits
could be caused by tau mutations, two transgenic mouse lines
were generated expressing a four-repeat isoform of human tau
or its mutant, containing one of the FTDP-17 mutations (WILD
mice and N279K mice). In open ﬁeld test, N279K mice showed
hyperactivity in locomotion and rearing. In prepulse inhibition
test, N279K mice but not Wild mice showed signiﬁcant deﬁcits.
Both transgenic mice, especially N279K mice, showed impair-
ment in acquisition of spatial learning in Morris water maze.
Although both N279K mice and Wild mice acquired passive
avoidance as well as non-transgenic mice, N279K mice but not
Wild mice showed severe deﬁcits in acquisition of active avoid-
ance. Histological analysis of the present mutant mice did not
show any signs of neuroﬁbrillary tangle formations in the brain,
and cognitive dysfunction seemed to precede such neuropatho-
logical changes or occur independently from them. The behav-
ioral phenotype of N279K mice mimics features of human
FTDP-17 and provides a basic model for elucidating mechanisms
underlying cognitive deﬁcits in not only FTDP-17, but also di-
verse tauopathies.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The discovery of mutations in the tau gene in frontotempo-
ral dementia and parkinsonism linked to chromosome 17
(FTDP-17) has demonstrated that tau dysfunction can cause
neurodegeneration and dementia with parkinsonism and has
provided unique opportunities to elucidate the disease mecha-Abbreviations: FTDP-17, frontotemporal dementia and parkinsonism
linked to chromosome 17; Tg, transgenic; NFT, neuroﬁbrillary tangle;
PPI, prepulse inhibition; ANOVA, analysis of variance
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doi:10.1016/j.febslet.2005.09.047nisms underling the tauopathies [1–5]. The functional conse-
quences of mutations have been studied in microtubule
assembly and tau protein aggregation experiments [6]. Most
of the exonic mutations investigated showed a markedly
reduced ability to promote microtubule assembly [7]. On the
other hand, intronic mutations found in the region of the exon
10 splice-donor site resulted in the overproduction of four-
repeat tau isoforms and reduced levels of tau isoforms with
three repeats [8,9]. The N279K mutation may be an exception.
Although it belongs to exonic mutations, it creates an exon
splice enhancer sequence and leads to increased splicing of
exon 10, resulting in the overproduction of four-repeat tau
isoforms [5,9–11].
Several lines of transgenic (Tg) mice expressing mutant tau
have been produced [12–18]. Tg mice expressing the P301L
mutation exhibit neuroﬁbrillary tangles (NFTs) and neuronal
loss in the anterior horn of the spinal cord, resulting in motor
dysfunctions and early death [12]. The deleterious defects have
made it diﬃcult to investigate whether they are demented. Tg
mice expressing the V337M mutation also reveal tau aggrega-
tion, which fulﬁlls the histological criteria for NFTs. They
show some behavioral impairment in the elevated plus maze,
suggesting that they may not be able to discriminate fearful
conditions from fearless ones [15].
In the present work, we focused on the N279K mutation,
since it as well as the P301L mutation lies in the 2nd repeat
of the microtubule binding domain (MBD), thus aﬀecting only
four-repeat tau isoforms. However, the N279K mutation is less
potent than the P301L mutation with respect to self-aggrega-
tion into ﬁlaments [19]. We have generated transgenic mice that
overexpressed human tau without (WILD mice) or with the
N279K mutation (N279K mice) and investigated whether these
mice show deﬁcits in learning ability or memory formation.2. Materials and methods
2.1. Generation of Tg mice expressing human tau
The human pathogenic mutation N279K was introduced into the
cDNA encoding human tau (383 amino acid residues) [20] using the
Quick Change Site-Directed Mutagenesis Kit (Stratagene). Transgenic
constructs (Wild and N279K) were inserted into the MoPrP vector
[21]. Transgenic mice were produced by microinjection of DNA intoation of European Biochemical Societies.
T. Taniguchi et al. / FEBS Letters 579 (2005) 5704–5712 5705pronuclei of C57BL/6 · SJL F2 hybrid mouse eggs. Two wild lines
(UBJAP4 and UBJAP18) and two N279K mutation lines (SJLB2
and SJLB9) were produced. Founder animals were intercrossed with
C57BL/6 mice to establish lines. Male homozygotes of SJLB9, UB-
JAP18, and non-transgenic littermates of SJLB9 at 12–13 months of
age were used for the study. Transgenic animal production and care
were carried out in cooperation with the Behavioral and Medical Sci-
ences Research Consortium (BMRC) and animal handling was done in
accordance with the ‘‘Guidelines for Animal Experimentation at
BMRC’’. The numbering of amino acid residues was based on the lon-
gest isoform of human tau (441 amino acid residues).
2.2. Antibodies
htaurg2, a rabbit polyclonal antibody speciﬁc for human tau, was
raised in rabbits against a synthetic peptide, TYGLGDRKDQGG,
corresponding to amino acid residues 17–28 of human tau. Tau (Dako)
is a rabbit polyclonal antibody, which reacts with both human and
mouse tau. RTA-C is a mouse monoclonal antibody, which reacts with
both human and mouse tau [22]. AT8, and AT180 (Innogenetics) are
proline-directed phosphorylation dependent mouse monoclonal anti-
bodies against tau, which recognize with proline-direct phosphoryla-
tion sites Ser-202/Thr-205 and Thr-231, respectively. HIA3 is a
rabbit polyclonal antibody, which reacts with tau phosphorylated at
Ser-320 [23].
2.3. Separation of exogenous human tau from endogenous mouse tau
Brains were homogenized in lysis buﬀer (50 mM Tris–HCl, pH 8.0,
10 mM EDTA, 100 mM NaCl, 10 mM sodium diphosphate decahy-
drate, 20 mM sodium ﬂuoride, and 2 mM sodium vanadate) contain-
ing 1% Triton and complete protease inhibitor (Roche), and
centrifuged at 10000 · g for 30 min. The supernatants (500 lg of pro-
tein/500 ll) were incubated without or with htaurg2 and precipitated
with protein A/G Sepharose (Amersham Biosciences) at 4 C for 2 h.
The supernatants left (Sup) and the precipitates (Ppt), washed with
PBS twice and resuspended to 500 ll were subjected to Western blot
analysis [23]. The relative levels of tau were determined by NIH image
software.
2.4. Immunoanalysis
The brain was dissected into seven regions: the olfactory bulb, cere-
bral cortex, striatum, hippocampus, diencephalon, brain stem (includ-
ing mesencephalon, pons, and medulla oblongata), and cerebellum.
Tissue homogenates in lysis buﬀer (50 mM Tris–HCl, pH 8.0,
10 mM EDTA, 100 mM NaCl, 10 mM sodium diphosphate decahy-
drate, 20 mM sodium ﬂuoride, and 2 mM sodium vanadate) contain-
ing 1% Triton and complete protease inhibitor (Roche) were
separated on 10% SDS–PAGE and subjected to Western blot analysis.
For the histological analysis, transgenic mice with human tau contain-
ing the N279K mutation were anesthetized and perfused with saline
and 4% paraformaldehyde/PBS. The brains were excised and postﬁxed
in 4% paraformaldehyde overnight and paraﬃn-embedded, sectioned
coronally at 5 lm, mounted, and then subjected to staining.
2.5. Behavioral analysis
Learning and memory function of the mice was investigated with a
speciﬁc test battery, including open-ﬁeld, prepulse inhibition (PPI) test,
water maze learning, passive avoidance learning, and active avoidance
learning. These tests were carried out in the order listed, from least
invasive to most invasive in order to minimize the chance that behav-
ioral properties are altered by prior test history [24]. Thirty male mice
(12–13 months of age; N279K mice, WILD mice and non-Tg mice;
n = 10 for each group) were examined. Each animal was housed in a
standard cage (10 · 17 · 10 cm) individually under a 12 h light–dark
cycle at 21 ± 1 C, with food and water available ad libitum. All the
experiments were performed in the light phase.
2.5.1. Open-ﬁeld test. A transparent cubic box without a ceiling
(30 · 30 · 30 cm) was housed in a ventilated sound-attenuating cham-
ber. An overhead incandescent bulb provided room lighting that mea-
sured approximately 110 lx inside the chamber. In addition, a fan
attached in the upper part of the wall at one end of the chamber pre-
sented a masking noise of 45 dB. On each X and Y bank of the open-
ﬁeld area, two infrared-ray beams were attached 2 cm above the ﬂoor
in a 10 cm interval, generating a ﬂip-ﬂop circuit between two beams.The total number of successive interceptions of two adjoining beams
on each bank was counted as the locomotion behavior. On the X bank,
the other 12 infrared-ray beams were attached 4.5 cm above the ﬂoor
in 2.5 cm intervals making ﬂip-ﬂop circuits. The total number of verti-
cal beam interceptions was counted as the rearing behavior. Each
mouse was allowed to explore freely in the open-ﬁeld area for 20 min.
2.5.2. Prepulse inhibition (PPI) test. Each mouse was enclosed in a
transparent acrylic box (7 · 7 · 10 cm) mounted on a wooden frame on
four rubber balls, which absorb vibration quickly, within a ventilated
enclosure. Whole-body startle responses of the mouse caused vibra-
tions of the box. These vibrations were converted to analog signals
by a piezoelectric accelerometer attached to the underside of the
box, and then digitized and recorded by a computer. The acoustic star-
tle pulse of broadband burst (115 dB, 50 ms) and tone prepulse
(1000 Hz, 85 dB, 30 ms) were presented via a speaker located in front
of the box. Light prepulse (115 lx, 30 ms) was onset of a white LED
ﬁxed at 3 cm above the box. Throughout the session, a background
noise level of 70 dB was maintained. The experimental session con-
sisted of two periods. During the ﬁrst period, 40 startle pulses were pre-
sented to test for basal startle responsiveness. The second period
included three diﬀerent trial types: a startle pulse alone, a tone prepulse
followed by a startle pulse, and a light prepulse followed by a startle
pulse. Prepulses preceded the startle pulse by either 50, 100, or
200 ms from a prepulse onset to the onset of the startle pulse. The
mean intertrial interval was 20 s (range from 10 to 30 s) throughout
the session. The startle response was recorded for 200 ms (measuring
the response every 1 ms) starting with the onset of the startle pulse.
PPI were indexed in terms of the PPI ratio. The ratio was calculated
using the formula: PPI ratio = PP/S, where PP is designated the mean
response of trial with prepulse, and S is designated the mean response
of trial without prepulse. Thus, a smaller ratio indicates a stronger PPI.
2.5.3. Water maze learning. A black circular pool (90 cm in diame-
ter) was ﬁlled with water made opaque by adding nontoxic black paint
to a depth of 22 cm, with a temperature of 22 ± 1 C. The pool was di-
vided into four virtual quadrants: north, south, east, and west. A
round platform (11 cm in diameter) was situated at the center of the
north quadrant of the pool, submerged 0.5 cm beneath the water sur-
face. The pool was enclosed with white featureless walls on which a
CCD camera and small black dolls were attached as extra-maze cues.
Each mouse was given ﬁve training trials per day for ﬁve consecutive
days. In each training trial, the mouse was placed into the water at
the middle site of the circular edge in the south, east, or west quadrant,
with the head facing the outer edge of the pool. A training trial termi-
nated when the mouse reached the platform and remained on it for
10 s. If the mouse did not ﬁnd the platform within 60 s, the mouse
was guided to the platform by the experimenter and kept there for
10 s. The order of releasing points varied from day to day with pseu-
dorandom sequences for each mouse. The intertrial interval was 30 s.
The escape latency of each training trial was measured up to a maxi-
mum of 60 s.
2.5.4. Passive avoidance learning. Each mouse was trained in a step-
through type passive avoidance apparatus consisting of two compart-
ments, one light (10 · 10 · 20 cm) and one dark (10 · 10 · 20 cm), with
a grid ﬂoor. A guillotine door separated these two compartments. In
the acquisition trial, the mouse was placed in the light compartment,
and 5 s later, the guillotine door was opened. When the mouse moved
into the dark compartment, the guillotine door was closed and 10 s la-
ter an electric shock (160 V, 0.50 mA, 3 s) was delivered through the
grid ﬂoor. Latency to enter the dark compartment was recorded.
Twenty-four hours later, a retention test trial was performed. The
mouse was placed back into the light compartment and latency to reen-
ter into the dark compartment was recorded, up to a maximum of
180 s. No shock was delivered in the retention test trial.
2.5.5. Active avoidance learning. A shuttle-box, consisting of two
equal compartments (10 · 10 · 20 cm) with a grid ﬂoor, was used.
These two compartments were connected by an open square gate
(8 · 8 cm). On both of the sidewalls of each compartment, 2 cm above
the ﬂoor and the 5 cm apart from the gate, two infrared-ray beams,
which could detect the animal response, were attached. The shuttle-
box was housed in a ventilated sound-attenuating chamber, and was
indirectly illuminated by white bulbs situated on the ceiling of the
chamber. Throughout the session, a background noise level of 64 dB
was maintained. A pure tone (1500 Hz, 85 dB) was presented by a
speaker 8 cm above the shuttle-box as a conditioned stimulus (CS).
An electric shock (140 V, 0.43 mA) to the grid ﬂoor was used as an
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for three consecutive days. Mice were placed in one compartment of
the shuttle-box and allowed to move between two compartments
throughout the training session. In each trial, the CS followed by the
US was presented. The CS preceded by 5 s the onset of the US and
overlapped it for a maximum of 15 s. If the mouse moved from one
compartment to the other compartment within 5 s after the onset of
the CS, the CS was terminated and the response was counted as suc-
cessful avoidance. However, if the mouse failed to move to the other
compartment, US was presented for a maximum of 15 s. While receiv-
ing US, if the mouse moved to the other compartment, both CS and
US ended immediately. The mean intertrial interval was varied with
a mean of 25 s (range from 10 to 40 s).
2.5.6. Data analysis. Data are expressed as means ± S.E.M. An
analysis of variance (ANOVA), with genotype as the between-subject
factor and repeated measure such as trial or day as the within-subject
factor, was conducted on the data. When necessary, data were ana-
lyzed using the post hoc t-test. In all statistical analyses, the level of sig-
niﬁcance was set at P < 0.05.3. Results
3.1. Generation of Tg mice expressing human tau
FTDP-17 with the missense mutation N279K is character-
ized as familial dementia and parkinsonism with tau pathology
in the frontal and temporal cortex, hippocampus, amygdala,
caudate nucleus, subthalamic nucleus, globus pallidus, substa-Fig. 1. Generation of transgenic mice expressing human tau. (a) Structure of
tau. Transgenic constructs were inserted into the unique XhoI restriction end
3rd, and 4th repeat of MBD, respectively. (b) Total tau expression. Total
subjected to Western blot analysis with a tau antibody (Tau), which reacts bo
The expression levels of tau (in panel b) were determined by densitometric ev
the means ± S.E.M. of three independent experiments using independent mi
mouse tau. Protein A/G precipitation of brain homogenates were performed
reacts human but not mouse tau (+). The precipitates (Ppt) and the supernat
RTA-C, htaurg2, and Tau as indicated. (e) Exogenous tau expression in trans
densitometric evaluation. The levels of tau in Sup(+) (endogenous tau) were
experiments using independent mice samples. Note that these data indicate e
be about 55% and 60% of endogenous mouse tau, respectively.tia nigra, striatum, and pontine tegmentum [10,11]. To investi-
gate eﬀects of the N279K mutation, transgenic mice were
generated expressing either human N279K or wild-type tau
cDNA containing exon 10 and lacking exons 2 and 3 [20],
which encodes four-repeat tau without amino-terminal inserts
(383 aa) (Fig. 1(a)). Two N279K mutation lines (SJLB9 and
SJLB2) and two Wild lines (UBJAP4 and UBJAP18) were pro-
duced. Since homozygous of SJLB9 (N279K mice) and UB-
JAP18 (WILD mice) expressed transgenic tau at roughly
equal levels, they were further analyzed in the study. N279K
mice and WILD mice expressed total tau approximately 55%
and 60% more than non-Tg mice, respectively (Fig. 1(b) and
(c)). To measure the levels of exogenous human tau and endog-
enous mouse tau, human tau was separated from mouse tau by
immunoprecipitateing human tau with a human speciﬁc anti-
tau antibody (htaurg2). As shown in Fig. 2, htaurg2 reacts
human tau but not mouse tau. Precipitate fractions of protein
A/G without htaurg2 contained no tau (Fig. 1(d), upper line,
Ppt ()), indicating that both human exogenous and mouse
endogenous tau were left in the supernatant fractions. On
the other hand, supernatant fractions of protein A/G with hta-
urg2 contained no human tau (Fig. 1(d), middle line, Sup (+)),
indicating that the all exogenous human tau was immunopre-
cipitated by htaurg2. Therefore, by comparing the amount of
tau protein in supernatant fractions of protein A/G without
htaurg2 (Fig. 1(d), lower line, Sup (); containing humanthe genes used for the generation of transgenic mice expressing human
onuclease site of the MoPrP vector. 1, 2, 3, and 4 indicate the 1st, 2nd,
brain homogenates (20 lg) were separated by 10% SDS–PAGE and
th human and mouse tau. (c) Overexpression of tau in transgenic mice.
aluation. The levels of tau in non-Tg were set as 100%. Data represent
ce samples. (d) Separation of exogenous human tau from endogenous
without () or with a human speciﬁc tau antibody (htaurg2), which
ants (Sup) were subjected to Western blot analysis with tau antibodies,
genic mice. The levels of tau (in panel d, lower line) were determined by
set as 100%. Data represent the means ± S.E.M. of three independent
xogenous human tau in WILD mice and N279K mice are calculated to
Fig. 2. Human tau expression in transgenic mice. Protein samples
from the olfactory bulb (lane 1), cerebral cortex (lane 2), striatum (lane
3), hippocampus (lane 4), diencephalon (lane 5), brain stem (lane 6),
cerebellum (lane 7), non-Tg whole brain (lane 9), and a blank (lane 8)
were separated by 10% SDS–PAGE and subjected to Western blot
analysis with a human speciﬁc tau antibody (htaurg2).
1.2
T. Taniguchi et al. / FEBS Letters 579 (2005) 5704–5712 5707tau and mouse tau) and with htaurg2 (Fig. 1(d), lower line,
Sup (+); containing mouse tau), the levels of exogenous human
tau of N279K mice and WILD mice were calculated to be
approximately 55% and 59% of endogenous mouse tau
(Fig. 1(e)). Western blots using an antibody (htaurg2) speciﬁc
for human tau proteins revealed that transgenic tau protein
was highly expressed in the hippocampus and striatum; moder-
ately expressed in the cerebral cortex, olfactory bulb, dienceph-
alon and cerebellum; and expressed at low levels in the brain
stem of N279K and WILD mice (Fig. 2). These mice were via-
ble and had normal feeding and body weight.
3.2. Cognitive/sensorimotor deﬁcits in tau transgenic mice
To know whether the transgenic mice were demented,
N279K mice, WILD mice, and non-Tg mice at 12–13 months
of age were evaluated with a comprehensive battery of tests.
3.2.1. Open ﬁeld test. In the open-ﬁeld test, N279K mice
showed a higher exploratory activity measured by locomotion0
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Fig. 3. Locomotion and rearing in the open ﬁeld test. A one-way
ANOVA and subsequent HSD test revealed a signiﬁcant eﬀect of
genotype on the locomotion score (F(2/27) = 12.56, P < 0.001) and in
the rearing score (F(2/27) = 16.39, P < 0.001) and signiﬁcant diﬀer-
ences between N279K mice and WILD mice (P < 0.001) and between
N279K mice and non-Tg mice (P < 0.001) in both behavioral
measures.and rearing score than WILD mice (P < 0.001) and non-Tg
mice (P < 0.001) and higher exploratory activity in rearing
than WILD mice (P < 0.001) and non-Tg mice (P < 0.001)
(Fig. 3). No signiﬁcant diﬀerences were observed between
WILD mice and non-Tg mice in locomotion (P = 0.958) and
rearing (P = 0.732) (Fig. 3).
3.2.2. Prepulse inhibition (PPI). Prepulse inhibition (PPI)
is a reduction of the startle response to an intense stimulus seen
when this stimulus is preceded by a weaker stimulus, which it-
self does not cause the startle response. It is used as an opera-
tional measure of sensorimotor gating, a process by which
excess or trivial stimuli are screened or gated out of awareness,
so that an individual can focus attention on the most salient
aspects of the stimulus-laden environment [25–27]. It can be
measured across a wide variety of species including humans,
nonhuman primates, and rodents [28,29]. In the ﬁrst period,
there were no signiﬁcant diﬀerences among genotypes in the le-
vel of startle responsiveness (F (2/27) = 1.24, P = 0.305), but all
genotypes showed habituation over the 40 startle pulse presen-
tations (P < 0.01). In the second period, N279K mice showed a
signiﬁcant deﬁcit in PPI compared with WILD mice (P < 0.05)
and non-Tg mice (P < 0.05) (Fig. 4). There was no signiﬁcant
diﬀerence between WILD mice and non-Tg mice (P = 0.989).
3.2.3. Water maze learning. We next performed the Morris
water maze, one of the hippocampus-dependent tasks [30]. All
genotypes started from the same level of performance (F < 1)
(Fig. 5). However, there were signiﬁcant diﬀerences in the
learning process between genotypes (P < 0.001). In non-Tg
mice and WILD mice, the mean escape latency decreased as
a function of training days. However, WILD mice required
more time to reach the platform. On the other hand, N279K
mice did not show any learning of the water maze task in
the training days (Fig. 5). These data indicate that overexpres-
sion of human tau impairs spatial leaning and that the N279K
mutation enhances the impairment.0.0
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Fig. 4. Prepulse inhibition with auditory and visual prepulse in the PPI
test. In the ﬁrst period, the mean startle responses of the initial and last
ﬁve trials were as follows: N279K mice; 9.5 ± 1.45 and 7.0 ± 0.85,
WILD mice; 8.2 ± 0.84 and 6.7 ± 0.80, and non-Tg mice; 10.8 ± 1.70
and 8.6 ± 1.07. A 3 (genotype) · 2 (block: initial vs. last) ANOVA
applied to these data yielded signiﬁcant eﬀect of block (F(1,27) = 10.75,
P < 0.01). The eﬀect of group (F(2/27) = 1.24, P = 0.31) and the
interaction of genotype · block (F < 1) were not signiﬁcant. In the
second period, the interval between prepulse and startle pulse had no
eﬀect on the degree of PPI in the present study (F < 1), therefore this
factor was collapsed. A 3 (genotype) · 2 (prepulse modality) ANOVA
yielded signiﬁcant eﬀects of genotype (F(2/27) = 5.92, P < 0.01) and
prepulse modality (F(1/27) = 40.30, P < 0.0001). Their interaction was
not signiﬁcant (F(2/27) = 1.87, P = 0.17).
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Fig. 5. Performance in the water maze task. Mean escape latency
during training. The averages of the mean escape latency of N279K
mice, WILD mice, and non-Tg mice on the ﬁrst day were 53.1 ± 2.08,
46.7 ± 3.86, and 52.1 ± 2.80 s, respectively, and a one-way ANOVA
applied to the data yielded no signiﬁcant genotype eﬀect (F < 1). A 3
(genotype) · 5 (training day) ANOVA yielded signiﬁcant main eﬀects
of genotype (F(2/27) = 10.61, P < 0.001) and training day (F(4/
108) = 25.86, P < 0.0001), and their interaction (F(8/108) = 6.12,
P < 0.0001). A subsequent analysis of genotype with the HSD test
revealed signiﬁcant diﬀerences between N279K mice and WILD mice
(P < 0.05) and between N279K mice and non-Tg mice (P < 0.001). The
diﬀerence between WILD mice and non-Tg mice was also signiﬁcant
on days 3, 4, and 5 (P < 0.05).
0
2
4
6
8
10
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
N279K
WILD
non-Tg
Blocks of Ten Trials
M
ea
n 
N
um
be
r o
f A
vo
id
an
ce
Day 1 Day 2 Day 3
Fig. 7. Performance in the active avoidance learning task. Mean
number of avoidance on each block composed of 10 trials. A 3
(genotype) · 3 (training day) · 5 (block) ANOVA yielded signiﬁcant
main eﬀects of genotype (F(2/27) = 10.66, P < 0.001), training day
5708 T. Taniguchi et al. / FEBS Letters 579 (2005) 5704–57123.2.4. Avoidance learning. We further determined if expres-
sion of the transgene impairs learning and memory function in
avoidance learning. In the passive avoidance learning, there
were no diﬀerences in the mean step-through latency to enter
the dark compartment among genotypes in the acquisition trial
(F < 1), indicating that all genotypes were similarly motivated
to enter the dark chamber. As a result of shock presentation in
the dark compartment, mean latency in the retention test trial
was prolonged greatly in all genotypes, indicating that all mice0
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Fig. 6. Step-through latency in the passive avoidance test. A 3
(genotype) · 2 (trial) ANOVA yielded signiﬁcant main eﬀect of trial
(F(1/27) = 235.29, P < 0.0001). The genotype (F < 1) and the interac-
tion of genotype · trial (F(2/27) = 1.60, P = 0.22) did not signiﬁcantly
aﬀect the results.acquired avoidance and memory retention tested 24 h after
training (Fig. 6). In auditory fear conditioning using the shut-
tle avoidance learning (active avoidance test), the successful
avoidance numbers of non-Tg mice and WILD mice increased
as a function of training days, although the overnight decre-
ment was observed in initial blocks of training days 2 and 3
(Fig. 7). The performance of N279K mice was poorer than
non-Tg mice (P < 0.001) and WILD mice (P < 0.01) over three
training days. There was no diﬀerence between non-Tg mice
and WILD mice (P = 0.803). These data indicate N279K mice
were highly impaired in active avoidance learning. These re-
sults could not be ascribed to diﬀerences in the basal rate of
the shuttle response among genotype because the number of
shuttle responses during each session yielded no genotype dif-
ferences (F(2/27) = 1.61, P = 0.22) and no signiﬁcant interac-
tion of genotype · training day (F < 1).
Cognitive/sensorimotor deﬁcits observed in these mice are
summarized in Table 1.(F(2/54) = 116.38, P < 0.0001), and block (F(4/108) = 83.38,
P < 0.0001). Also, the ﬁrst-order interaction between genotype and
training day was signiﬁcant (F(4/54) = 4.36, P < 0.005). A subsequent
analysis of genotype with the HSD test revealed signiﬁcant diﬀerences
between N279K mice and WILD mice (P < 0.001) and between
N279K mice and non-Tg mice (P < 0.01), but no diﬀerence between
non-Tg mice and WILD mice (P = 0.803). There were no genotype
diﬀerences in the number of shuttle responses during each session. A 3
(genotype) · 3 (training day) ANOVA yielded no signiﬁcant main
eﬀect of genotype (F(2/27) = 1.61, P = 0.22) and interaction of geno-
type · training day (F < 1).
Table 1
Summary of behavioral phenotypes compared to non-Tg
Human tau transgenic
N279K WILD
Open-ﬁeld locomotion Hyperactive Normal
Open-ﬁeld rearing Hyperactive Normal
PPI Deﬁcit Normal
Water maze Severe deﬁcit Mild deﬁcit
Passive avoidance Normal Normal
Active avoidance Deﬁcit Normal
Normal means the performance is comparable to that of non-Tg.
Fig. 8. Phosporylation state of tau in tau transgenic mice. Protein
samples from brain regions were separated on 10% SDS–PAGE and
tau phosphorylation was analyzed by Western blot analysis using anti-
phosphotau antibodies indicated.
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Hyperphosphorylated tau loses the tubulin assembly-pro-
moting activity [23,31], and abnormal phosphorylation of tau
may be a crucial step preceding neuroﬁbrillary formation
[32]. Therefore we investigated the phosphorylation states of
tau in transgenic mice. In N279K mice, signal was detected
in the hippocampus on Western blotting with AT8, and in
the olfactory bulb, cerebellum, hippocampus, diencephalons,
cerebral cortex and brain stem on Western blotting with
AT180 (Fig. 8). We also observed phosphorylated tau in these
brain regions, especially in the hippocampus of WILD mice.Fig. 9. Tau accumulation at the distal region of CA2 and CA3 of the hippocam
paraformaldehyde/PBS. Coronal sections of the hippocampus were subject
staining, (c) Bodian staining, and (d) anti-tau immunostaining (htaurg2).Phosphorylated tau was virtually not detected by AT8 and
AT180 in non-Tg mice. It should be noted that relative inten-
sities of signals among brain regions diﬀered from mouse to
mouse, although signals were always detected in the hippocam-
pus of N279K mice.
3.4. Accumulation of tau in the hippocampus of N279K mice
Although light microscopic histochemical analysis demon-
strated diﬀuse tau immunoreactivities throughout the brain,
no apparent neuronal loss and no neuroﬁbrillary tangles were
observed in these brain regions of both N279K and WILD
mice at up to 13 months of age. Although Western blotting
analysis detected phosphorylated tau in the brain (Fig. 8), we
failed to detect any immunoreactivity with AT8 and AT180.
We observed an increase in silver staining at the distal region
of CA2 and CA3 in the hippocampus (Fig. 9(c)). Such an area
seemed to be similarly stained with anti-human tau antibody
(htaurg2) (Fig. 9(d)). The area was identiﬁed as dendritic neu-
rites rather than perikaryal or axonal distribution of pyramidal
neurons in CA2 and CA3 (Fig. 9) [33]. Neither antibodies to
recognize phosphorylated tau, such as AT8, AT180 and
HIA3, or a antibody to recognize ubiquitin stained such den-
dritic accumulation of tau [34,35].4. Discussion
Several lines of Tg mice expressing wild or mutant tau have
been reported. Tg mice expressing either three- or four-repeat
type of wild tau show hyperphosphorylated tau, although they
do not form NFTs in the brain [36–39]. Tg mice expressing thepus. N279K mice were anesthetized and perfused with saline and 4%
ed to staining. Light photomicrographs of (a) HE staining, (b) Nissl
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tion, which fulﬁlls the histological criteria for NFTs [12,15]. In
the present work, we generated transgenic mice expressing hu-
man tau without (WILD) or with one of the FTDP-17 muta-
tions (N279K). SJLB9 (N279K mice) and UBJAP18 (WILD
mice) expressing transgenic tau at roughly equal levels
(Fig. 1(c) and (e)) and equal tissue distribution (Fig. 2) were
used in the study.
At the age of 12 months, the tau transgenic mice showed
phosphorylated tau in the brain regions, especially in the hip-
pocampus by Western blotting (Fig. 8). But the relative inten-
sities among brain regions diﬀered from mouse to mouse and
the intensity of phosphorylation did not correlate well with
the degree of cognitive deﬁcits (T. Taniguchi, unpublished
data). Histological analysis did not detect phosphorylated
tau in the brain regions, suggesting the amount of phosphory-
lated tau was little. These results indicate that tau phosphory-
lation may not be indispensable for the cognitive deﬁcits
discussed below, although it should play an important role
on certain aspects of tau dysfunction.
We could not detect any sign of tangle formation, although
we have examined whether NFTs are formed in their brains up
to 13 months of age extensively. Neither Congo red nor Thio-
ﬂavin dyes showed any birefringence, which was expected for
abnormal ﬁbril formation, as seen in tau inclusions of Alzhei-
mers disease. These ﬁndings suggest that pathological oligo-
mers of tau protein, which could not be detected by light
microscopy, may be resultantly a toxic form that causes neuro-
nal dysfunction. The present Tg mice with the N279K muta-
tion may have failed to reduce such pathological oligomers
of tau protein, and the increase in silver staining at the distal
region of CA2 and CA3 in the hippocampus (Fig. 9(c) and
(d)) may reﬂect toxic tau accumulation of N279K mice.
Huntingtons disease (HD) is another neurodegenerative dis-
order caused by an abnormal polyglutamine expansion within
the huntingtin protein [40]. Like tauopathies, the aggregation
of huntingtin protein into microscopic intracellular deposits
is observed in aﬀected brains [41]. The relationship between
huntingtin deposition and neurodegeneration is also contro-
versial. Sometimes deposition formation has been associated
with neurodegeneration [42–44], and at other times, there has
been no or a negative correlation [45–47]. In the neuronal cell
model of HD, deposit formation reduced the risk of cell death
[48]. Thus, we should take into consideration that intracellular
deposit formation, such as NFTs, would be a beneﬁcial coping
response to reduce intracellular levels of abnormal tau,
although an intraneuronal condition where NFTs were formed
is undoubtedly unpreferable to neurons and their normal func-
tions. More intense and thorough biochemical analysis of the
tau in N279K mice such as insolubility would reveal what form
of tau is toxic to neurons and whether NFT formation is a cop-
ing response or not.
The main issue of the present study is to elucidate whether
mice expressing human tau or its mutant exhibit any cogni-
tive/sensorimotor deﬁcits or what kind of features observed
in human FTDP patients would be mimicked by these mice.
In the open-ﬁeld test, N279K mice showed signiﬁcant hyper-
activity in locomotion and rearing than WILD mice and non-
Tg mice (Fig. 3) without habituation, suggesting that it would
mimic loitering or sauntering behaviors, which are often ob-
served in demented patients, including FTDP-17. It is also con-
sistent with the clinical phenotypes, such as anxiety andaggressiveness, in FTDP-17 patients with N279K mutation
[10].
PPI is modulated by a well-characterized neural circuit con-
necting limbic cortical regions and subcortical dopaminergic
systems, and ultimately innervating pontine circuitry via sub-
pallidal eﬀerent projections [49]. Deﬁcits in PPI have been
noted in patients with schizophrenia, obsessive compulsive dis-
order, Huntingtons disease, and attention deﬁcit disorder,
which are all characterized by impairments of sensorimotor
gating or cognitive deﬁcits [29,50]. Furthermore, patients with
Parkinson disease have been reported to exhibit altered pre-
pulse modiﬁcation of trigeminal reﬂex blinks [51,52]. PPI with
visual and auditory prepulse was signiﬁcantly disturbed in
N279K mice, but not in WILD and non-Tg mice (Fig. 4).
Although PPI have apparently not been tested in FTDP-17 pa-
tients, these sensorimotor gating deﬁcits of N279K mice may
provide information to better understand mechanisms under-
lying parkinsonism observed in FTDP-17 patients.
Spatial learning was examined by the Morris Water Maze.
N279K mice displayed a striking impairment and WILD mice
also displayed a signiﬁcant impairment compared with non-Tg
mice (Fig. 5). These results are concurrent with the deﬁcits in
in vivo hippocampal LTP formation (data not shown) [53],
which is assumed to underlie plastic changes associated with
learning and memory [54]. It is suggested that expression of
human tau in these animals induces an impairment of synaptic
plasticity in the hippocampus, leading to reduced ability in
spatial learning. Furthermore, the N279K mutation enhances
the impairments and may cause abnormal accumulation of
tau at the distal region of CA2 and CA3 in the hippocampus
(Fig. 9).
Learning and memory formation of an aversive experience
was examined by the passive avoidance and the active avoid-
ance. Although all mice acquired avoidance behavior in the
passive avoidance paradigm (Fig. 6), N279K mice did not ac-
quire avoidance behavior well in the active avoidance para-
digm (Fig. 7). The active avoidance paradigm used here was
based on Pavlovian fear conditioning. A large body of evi-
dence suggests that the amygdala is a likely site of the plasticity
underling memory storage of conditioned fear as well as an
unconditioned one [55]. The retardation of learning in fear
conditioning of N279K mice could be explained by functional
impairments in the amygdala, although this has not been stud-
ied extensively. This notion is supported by pathological and
clinical ﬁndings that atrophy of the amygdala is demonstrated
in FTDP-17 patients with the N279K mutation [10], and that
impairment of emotional event memory in Alzheimers disease
is related to intensity of amygdala damage [56].
Mutations in the tau gene are classiﬁed into two genotypes.
One consists of missense mutations in the MBD or the C-ter-
minal region and the other consists of intronic mutations that
change the ratio of three-repeat to four-repeat tau isoforms.
The functional consequences of missense mutations come from
the microtubule assembly experiments. They showed a mark-
edly reduced ability to promote microtubule assembly. The
N279K mutation may be an exception since it creates an exon
splice enhancer sequence and leads to increased splicing of
exon 10. The N279K mutation increased 4-repeat tau
[5,10,11], but did not reduce the potential to promote microtu-
bule assembly [57].
N279K mice and WILD mice expressed roughly equal levels
of the 4-repeat tau protein and equal distribution in brain; nev-
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learning and in LTP production [53] than Wild mice. Further-
more, N279K mice, but not WILD mice, showed deﬁcits in
fear conditioning and PPI. Although the pathological and/or
biochemical origins of the impairments of N279K mice require
further investigation, these data suggest a speciﬁc role for the
N279K mutation in addition to the over-production of the 4-
repeat tau protein. SJLB2, another line of tau transgenic mice
with N279K mutation also show same kinds of cognitive def-
icits as N279K mice, conﬁrming that the deﬁcits are due to tau
mutation, not due to insertion eﬀects of the transgene (data not
shown).
We report here that a transgenic mouse line expressing hu-
man tau with the N279K mutation develops hyperactivity in
locomotion and rearing and deﬁcits in prepulse inhibition, spa-
tial and fear learning and memory formation before or without
formation of neuroﬁbrillary tangles. The behavioral pheno-
types of N279K mice mimic some features of human FTDP-
17 [58] and provide a basic model for elucidating mechanisms
underlying cognitive deﬁcits in not only FTDP-17, but also di-
verse tauopathies. They may be of value for pharmacological
evaluation of novel drugs.
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